デフォルト表紙
市場調査レポート
商品コード
1403342

セラノスティクス市場の2030年までの予測: 疾患タイプ別、技術別、エンドユーザー別、地域別の世界分析

Theranostics Market Forecasts to 2030 - Global Analysis By Disease Type (Neurological Disorder, Immunological Disorder, Cardiovascular Disease, Oncology and Other Disease Types), Technology, End User and By Geography

出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
セラノスティクス市場の2030年までの予測: 疾患タイプ別、技術別、エンドユーザー別、地域別の世界分析
出版日: 2024年01月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、セラノスティクスの世界市場は2023年に7億米ドルを占め、予測期間中にCAGR 11.8%で成長し、2030年には17億米ドルに達すると予測されています。

セラノスティクス」と呼ばれる新たな医療分野は、治療法と診断法を融合させ、一つのまとまった手順としています。「治療」と「診断」を組み合わせた「セラノスティクス」は、患者治療の両側面をいかに統合すべきかを強調しています。各患者のユニークな特徴や疾病プロファイルに基づき、正確で個別化された治療計画を提供しようとするものです。セラノスティクスの分野では、分子イメージング、遺伝子検査、バイオマーカー分析、分子プロファイリングなどの高度な診断法が用いられています。

診断技術の進歩

分子イメージング、次世代シークエンシング(NGS)、陽電子放射断層撮影(PET)や磁気共鳴画像法(MRI)を含む高解像度画像モダリティなどの高度な診断技術により、疾病診断の精度と感度は向上しています。病気に関連する特定のバイオマーカー、遺伝子変異、分子標的を同定する能力は、このような精密さによって可能となり、これはテーラーメード医薬品の開発に向けたセラノスティクスにおいて不可欠です。さらに、セラノスティクスの分野で早期に同定することにより、迅速な介入とカスタマイズされた治療計画が可能になり、より強力で集中的な治療が可能になることで、患者の転帰が向上する可能性があります。

セラノスティクス検査に関する適切な規制の欠如

正確で定義された法律がないため、セラノスティクス検査のクリアランス手順、バリデーション仕様、品質基準はすべて不明確である可能性があります。この予測不可能性は、新規診断薬の創出と使用を妨げ、画期的な薬剤の発売を遅らせる可能性があります。不明確な規制の枠組みや国際的に異なる要件により、セラノシス検査の市場導入が遅れる可能性があります。企業は複雑な規制手続きに対応するのが困難となる可能性があり、その結果、承認までの待ち時間が長くなって市場成長が阻害される可能性があります。

研究開発イニシアチブの増加

研究開発費は最先端の診断機器や技術の創出を支えています。これらの開発により、診断検査の感度、特異性、精度が向上し、疾患バイオマーカー、遺伝子変異、分子標的をより正確に同定できるようになります。セラノスティックスは、カスタマイズされた治療計画を指示するために、診断法の改善に大きく依存しています。セラノスティクスの商品・サービスの拡大や商業化は、研究開発の成果が市場で成功することによって促進され、患者やヘルスケア専門家がより個別化された効率的な治療法を利用できるようになります。

規制上の課題

新たなセラノスティック検査や製品の上市は、厳しい規制要件、複雑な承認手続き、長期化する薬事承認プロセスによって遅れる可能性があります。このため、患者が個別化医療や最先端技術を予定通りに受けることが難しくなる可能性があります。承認手続きや規制要件が地域によって異なるため、市場の分断が生じる可能性があります。地理的に異なる場所では、規制要件が一貫していないため、セラノスティック検査へのアクセスが不平等になる可能性があり、その結果、これらの検査の利用可能性や取り込みに差が生じる可能性があります。

COVID-19の影響

今回の流行は、迅速かつ正確な診断検査がいかに重要であるかを浮き彫りにしました。SARS-CoV-2を特定するために、PCRや核酸増幅に基づくアッセイなどの分子診断法の使用が劇的に増加しました。このように分子診断法が注目されることで、セラノスティクスが扱うような他の病気の治療においても、同等の方法が重要であることが浮き彫りになった。対面での診察を最小限に抑え、治療の継続性を維持するために、遠隔医療や遠隔モニタリングの技術がますます支持されるようになった。この変化は、遠隔モニタリングや診断を含むセラノスティクス戦術の実施方法に影響を与える可能性があります。

予測期間中、神経疾患分野が最大となる見込み

神経疾患分野は、脳、脊髄、末梢神経を含む幅広い疾患が神経疾患と呼ばれるため、有利な成長を遂げると推定されます。これらの疾患には、多発性硬化症、てんかん、パーキンソン病、アルツハイマー病、さまざまな神経障害などが含まれます。さらに、セラノスティックスは、遺伝子プロファイリング、分子バイオマーカー、高度な画像診断法を駆使して、神経疾患の早期かつ正確な同定を促進します。このように、正確な診断機器は、これらの病態に関連する特定のバイオマーカーや病理学的変化を検出することにより、病気の追跡や予後をサポートします。

予測期間中、ポリメラーゼ連鎖反応(PCR)分野が最も高いCAGRが見込まれる

ポリメラーゼ連鎖反応(PCR)分野は、特に診断と予後の用途にポリメラーゼ連鎖反応(PCR)が不可欠であるため、予測期間中に最も高いCAGRの成長が見込まれます。セラノスティックスは、分子生物学的技術であるポリメラーゼ連鎖反応(PCR)を用いて、特定のDNAまたはRNA配列を同定し増幅します。PCRは感染症、遺伝子変異、様々な疾患と関連するバイオマーカーを見つけるための重要なツールです。PCRに基づく補完的診断技術は、患者が特定の治療にどのように反応するかを予測することができます。従ってヘルスケア専門家は、特定の遺伝子変異やバイオマーカーを分析するためにPCRを採用することで、各患者に最適な治療方針を選択することができ、治療成果を最大化することができます。

最大のシェアを持つ地域

北米は、予測期間中最大の市場シェアを占めると予測されます。これは、北米でがん患者がますます多くなるにつれて、より効率的でカスタマイズされた治療法の選択に対するニーズが高まっているためです。セラノスティックスは、特定のバイオマーカーに基づく標的医薬品を提供することで、より正確ながん診断と治療に役立ちます。さらに、個別化医療技術はますます普及しています。そのため、遺伝子構成、病気の特徴、バイオマーカーに応じて患者ごとに治療法をカスタマイズすることが目標となり、市場の成長を牽引しています。

CAGRが最も高い地域:

予測期間中、欧州のCAGRが最も高いと予測されます。がんやその他の慢性疾患の罹患率の増加により、より個別化された効率的な治療法に対するニーズが高まっているためです。セラノスティクスは、特定のバイオマーカーに基づいてオーダーメイドの医薬品を提供できることから、患者の転帰を改善することが期待され、注目を集めました。アジア太平洋地域では、個別化医療、分子診断、高度な画像技術などのプロジェクトを含むヘルスケア・インフラの強化に多額の投資が行われています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます:

  • 企業プロファイル
    • 追加市場プレイヤーの包括的プロファイリング(3社まで)
    • 主要企業のSWOT分析(3社まで)
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR(注:フィージビリティチェックによる)
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査ソース
    • 1次調査ソース
    • 2次調査ソース
    • 前提条件

第3章 市場動向分析

  • 促進要因
  • 抑制要因
  • 機会
  • 脅威
  • 技術分析
  • エンドユーザー分析
  • 新興市場
  • 新型コロナウイルス感染症(COVID-19)の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界のセラノスティクス市場:疾患タイプ別

  • 神経障害
  • 免疫疾患
  • 循環器疾患
  • 腫瘍学
    • 結腸直腸がん
    • 乳がん
    • 子宮頸がん
    • 肺がん
  • その他の疾患タイプ

第6章 世界のセラノスティクス市場:技術別

  • In situハイブリダイゼーション
  • ポリメラーゼ連鎖反応(PCR)
  • 免疫組織化学
  • シーケンス
  • その他の技術

第7章 世界のセラノスティクス市場:エンドユーザー別

  • 診断ラボ
  • 病院とクリニック
  • その他のエンドユーザー

第8章 世界のセラノスティクス市場:地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋地域
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東とアフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東とアフリカ

第9章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品の発売
  • 事業拡大
  • その他の主要戦略

第10章 企業プロファイル

  • Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific Inc.
  • Beckman Coulter, Inc.
  • QIAGEN
  • Abbott Laboratories
  • Myriad Genetics, Inc.
  • Foundation Medicine, Inc.
  • AmeriPath, Inc.
  • Focus Diagnostics
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Leica Biosystems Nussloch GmBH
  • GE Healthcare
  • Pfizer, Inc.
図表

List of Tables

  • Table 1 Global Theranostics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 3 Global Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 4 Global Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 5 Global Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 6 Global Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 7 Global Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 8 Global Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 9 Global Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 10 Global Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 11 Global Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 12 Global Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 13 Global Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 14 Global Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 15 Global Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 16 Global Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 17 Global Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 18 Global Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 19 Global Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 20 Global Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 21 Global Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 22 North America Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 23 North America Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 24 North America Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 25 North America Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 26 North America Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 27 North America Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 28 North America Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 29 North America Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 30 North America Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 31 North America Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 32 North America Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 33 North America Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 34 North America Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 35 North America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 36 North America Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 37 North America Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 38 North America Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 39 North America Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 40 North America Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 41 North America Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 42 North America Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 43 Europe Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 44 Europe Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 45 Europe Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 46 Europe Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 47 Europe Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 48 Europe Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 49 Europe Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 50 Europe Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 51 Europe Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 52 Europe Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 53 Europe Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 54 Europe Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 55 Europe Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 56 Europe Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 57 Europe Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 58 Europe Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 59 Europe Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 60 Europe Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 61 Europe Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 62 Europe Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 63 Europe Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 64 Asia Pacific Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 65 Asia Pacific Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 66 Asia Pacific Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 67 Asia Pacific Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 68 Asia Pacific Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 69 Asia Pacific Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 70 Asia Pacific Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 71 Asia Pacific Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 72 Asia Pacific Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 73 Asia Pacific Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 74 Asia Pacific Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 75 Asia Pacific Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 76 Asia Pacific Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 77 Asia Pacific Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 78 Asia Pacific Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 79 Asia Pacific Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 80 Asia Pacific Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 81 Asia Pacific Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 82 Asia Pacific Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 83 Asia Pacific Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 84 Asia Pacific Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 85 South America Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 86 South America Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 87 South America Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 88 South America Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 89 South America Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 90 South America Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 91 South America Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 92 South America Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 93 South America Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 94 South America Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 95 South America Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 96 South America Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 97 South America Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 98 South America Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 99 South America Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 100 South America Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 101 South America Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 102 South America Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 103 South America Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 104 South America Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 105 South America Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 106 Middle East & Africa Theranostics Market Outlook, By Country (2021-2030) ($MN)
  • Table 107 Middle East & Africa Theranostics Market Outlook, By Disease Type (2021-2030) ($MN)
  • Table 108 Middle East & Africa Theranostics Market Outlook, By Neurological Disorder (2021-2030) ($MN)
  • Table 109 Middle East & Africa Theranostics Market Outlook, By Immunological Disorder (2021-2030) ($MN)
  • Table 110 Middle East & Africa Theranostics Market Outlook, By Cardiovascular Disease (2021-2030) ($MN)
  • Table 111 Middle East & Africa Theranostics Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 112 Middle East & Africa Theranostics Market Outlook, By Colorectal Cancer (2021-2030) ($MN)
  • Table 113 Middle East & Africa Theranostics Market Outlook, By Breast Cancer (2021-2030) ($MN)
  • Table 114 Middle East & Africa Theranostics Market Outlook, By Cervical Cancer (2021-2030) ($MN)
  • Table 115 Middle East & Africa Theranostics Market Outlook, By Lung Cancer (2021-2030) ($MN)
  • Table 116 Middle East & Africa Theranostics Market Outlook, By Other Disease Types (2021-2030) ($MN)
  • Table 117 Middle East & Africa Theranostics Market Outlook, By Technology (2021-2030) ($MN)
  • Table 118 Middle East & Africa Theranostics Market Outlook, By In Situ Hybridization (2021-2030) ($MN)
  • Table 119 Middle East & Africa Theranostics Market Outlook, By Polymerase Chain Reaction (PCR) (2021-2030) ($MN)
  • Table 120 Middle East & Africa Theranostics Market Outlook, By Immunohistochemistry (2021-2030) ($MN)
  • Table 121 Middle East & Africa Theranostics Market Outlook, By Sequencing (2021-2030) ($MN)
  • Table 122 Middle East & Africa Theranostics Market Outlook, By Other TechnologIEs (2021-2030) ($MN)
  • Table 123 Middle East & Africa Theranostics Market Outlook, By End User (2021-2030) ($MN)
  • Table 124 Middle East & Africa Theranostics Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 125 Middle East & Africa Theranostics Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 126 Middle East & Africa Theranostics Market Outlook, By Other End Users (2021-2030) ($MN)
目次
Product Code: SMRC24567

According to Stratistics MRC, the Global Theranostics Market is accounted for $0.7 billion in 2023 and is expected to reach $1.7 billion by 2030 growing at a CAGR of 11.8% during the forecast period. A new area of medicine called "theranostics" blends therapeutic and diagnostic methods into a single, cohesive procedure. Combining the terms "therapy" and "diagnostics," "theranostics" emphasizes how both aspects of patient treatment should be integrated. It seeks to offer accurate and individualized treatment plans based on the unique traits and illness profiles of each patient. Advanced diagnostic methods such as molecular imaging, genetic testing, biomarker analysis, and molecular profiling are used in the field of theranostics.

Market Dynamics:

Driver:

Advancements in diagnostic technologies

The accuracy and sensitivity of illness diagnosis have been improved by sophisticated diagnostic technologies, such as molecular imaging, next-generation sequencing (NGS), and high-resolution imaging modalities including positron emission tomography (PET) and magnetic resonance imaging (MRI). The ability to identify certain biomarkers, genetic variants, or molecular targets linked to illnesses is made possible by this precision, and this is essential in theranostics for the development of tailored medicines. Moreover, early identification in the field of theranostics allows for prompt intervention and customized treatment plans, which may enhance patient outcomes by enabling more powerful and focused therapy.

Restraint:

Lack of properly defined regulations for theranostics tests

The clearance procedure, validation specifications, and quality criteria for theranostic testing might all be unclear in the absence of precise and defined laws. This unpredictability may impede the creation and use of novel diagnostics, delaying the release of ground-breaking theranostic products. Theranostic test market introduction may be delayed by unclear regulatory frameworks and disparate international requirements. Businesses may have trouble navigating complicated regulatory procedures, which might lead to longer wait times for clearances impeding the market growth.

Opportunity:

Increasing research and development initiatives

R&D expenditures support the creation of cutting-edge diagnostic instruments and technology. These developments improve diagnostic test sensitivity, specificity, and accuracy, making it possible to identify disease biomarkers, genetic variants, and molecular targets more accurately. Theranostics relies heavily on improved diagnostics to direct customized treatment plans. The expansion and commercialization of theranostic goods and services are facilitated by successful R&D outcomes on the market giving patients and healthcare professionals access to more individualized and efficient treatment alternatives.

Threat:

Regulatory challenges

New theranostic test and product launches might be delayed by onerous regulatory requirements, convoluted approval procedures, and protracted regulatory approval processes. This hold-up may make it more difficult for patients to receive individualized care and cutting-edge technologies on schedule. Market fragmentation may arise due to variations in approval procedures and regulatory requirements across different locations. Different geographic locations may experience unequal access to theranostic testing due to inconsistent regulatory requirements, which might lead to differences in the availability and uptake of these tests.

COVID-19 Impact

The epidemic brought to light how crucial quick and precise diagnostic testing is. The use of molecular diagnostic methods, such as PCR and assays based on nucleic acid amplification, has increased dramatically in order to identify SARS-CoV-2. The importance of comparable methods in treating other illnesses, such as those addressed by theranostics, has been highlighted by this focus on molecular diagnostics. In order to minimize in-person encounters and maintain continuity of treatment, telemedicine and remote monitoring technologies gained increasing traction. This change may affect how theranostics tactics that include remote monitoring and diagnostics are implemented.

The neurological disorder segment is expected to be the largest during the forecast period

The neurological disorder segment is estimated to have a lucrative growth, owing to a wide range of illnesses involving the brain, spinal cord, and peripheral nerves are referred to as neurological diseases. These illnesses include multiple sclerosis, epilepsy, Parkinson's disease, Alzheimer's disease, and different neuropathies. Moreover, theranostics makes use of genetic profiling, molecular biomarkers, and sophisticated imaging methods to facilitate the early and precise identification of neurological illnesses. Thus, accurate diagnostic instruments support illness tracking and prognosis by detecting certain biomarkers or pathological alterations linked to these conditions.

The polymerase chain reaction (PCR) segment is expected to have the highest CAGR during the forecast period

The polymerase chain reaction (PCR) segment is anticipated to witness the highest CAGR growth during the forecast period, as polymerase chain reaction (PCR) is essential, particularly for diagnostic and prognostic uses. Theranostics uses polymerase chain reaction (PCR), a molecular biology technique, to identify and amplify specific DNA or RNA sequences. PCR is a vital tool for finding infections, genetic variants, and biomarkers linked to a variety of disorders. Complementary diagnostic techniques based on PCR can forecast how a patient will react to specific treatments. Hence healthcare professionals may choose the best course of action for each patient by employing PCR to analyze certain genetic variants or biomarkers, which maximizes therapeutic outcomes.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the need for more efficient and customized treatment choices that have grown as cancer cases become increasingly common in North America. Theranostics helps with more accurate cancer diagnosis and therapy by providing targeted medicines based on certain biomarkers. Moreover, personalized medicine techniques are becoming more and more popular. Thus, the goal is to customize therapies for each patient according to their genetic composition, illness features, and biomarkers driving the growth of the market.

Region with highest CAGR:

Europe is projected to have the highest CAGR over the forecast period, as growing cancer and other chronic illness incidence has increased need for more individualized and efficient treatment alternatives. Theranostics attracted attention for its promise to enhance patient outcomes because of its capacity to provide tailored medicines based on certain biomarkers. The Asia Pacific area has seen significant investments in enhancing its healthcare infrastructure, encompassing projects in personalized medicine, molecular diagnostics, and sophisticated imaging technology.

Key players in the market:

Some of the key players profiled in the Theranostics Market include Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Beckman Coulter, Inc., QIAGEN, Abbott Laboratories, Myriad Genetics, Inc., Foundation Medicine, Inc., AmeriPath, Inc., Focus Diagnostics, Illumina, Inc., Agilent Technologies, Inc., Leica Biosystems Nussloch GmBH, GE Healthcare and Pfizer, Inc.

Key Developments:

In November 2023, Roche launches automated serology hepatitis E virus tests, including a test to detect acute HEV infections, recommended in the new WHO 2023 Essential Diagnostics List. The tests complete Roche's panel used for the differential diagnosis of acute viral hepatitis caused by the hepatitis A, B, C and E viruses.

In October 2023, Thermo Fisher Scientific to Acquire Olink, a Leader in Next-Generation Proteomics, and the transaction values Olink at approximately $3.1 billion which includes net cash of approximately $143 million.

In October 2023, Beckman Coulter Diagnostics, announced it acquired StoCastic, LLC. a leading artificial intelligence company that provides evidence-based decision support for hospital emergency departments (ED).

Disease Types Covered:

  • Neurological Disorder
  • Immunological Disorder
  • Cardiovascular Disease
  • Oncology
  • Other Disease Types

Technologies Covered:

  • In Situ Hybridization
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry
  • Sequencing
  • Other Technologies

End Users Covered:

  • Diagnostic Laboratories
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Theranostics Market, By Disease Type

  • 5.1 Introduction
  • 5.2 Neurological Disorder
  • 5.3 Immunological Disorder
  • 5.4 Cardiovascular Disease
  • 5.5 Oncology
    • 5.5.1 Colorectal Cancer
    • 5.5.2 Breast Cancer
    • 5.5.3 Cervical Cancer
    • 5.5.4 Lung Cancer
  • 5.6 Other Disease Types

6 Global Theranostics Market, By Technology

  • 6.1 Introduction
  • 6.2 In Situ Hybridization
  • 6.3 Polymerase Chain Reaction (PCR)
  • 6.4 Immunohistochemistry
  • 6.5 Sequencing
  • 6.6 Other Technologies

7 Global Theranostics Market, By End User

  • 7.1 Introduction
  • 7.2 Diagnostic Laboratories
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Theranostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.8 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Hoffmann-La Roche Ltd
  • 10.2 Thermo Fisher Scientific Inc.
  • 10.3 Beckman Coulter, Inc.
  • 10.4 QIAGEN
  • 10.5 Abbott Laboratories
  • 10.6 Myriad Genetics, Inc.
  • 10.7 Foundation Medicine, Inc.
  • 10.8 AmeriPath, Inc.
  • 10.9 Focus Diagnostics
  • 10.10 Illumina, Inc.
  • 10.11 Agilent Technologies, Inc.
  • 10.12 Leica Biosystems Nussloch GmBH
  • 10.13 GE Healthcare
  • 10.14 Pfizer, Inc.